Lakefront Biotherapeutics NV (XAMS:LKFT) Accounts Payable: €96 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XAMS:LKFT Lakefront Biotherapeutics NV XAMS:LKFT
57 GF Score
Price €24.50
GF Value €109.50
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Lakefront Biotherapeutics NV Accounts Payable?

Lakefront Biotherapeutics NV XAMS:LKFT -1.13% 57 Accounts Payable is €96 Mil as of Mar. 2026. GuruFocus rates XAMS:LKFT with a GF Score™ of 57/100 and a GF Value™ of €109.50 (Possible Value Trap). The stock has 4 warning signs investors should review.

Lakefront Biotherapeutics NV's Accounts Payable for the quarter that ended in Mar. 2026 was €96 Mil.

Lakefront Biotherapeutics NV's quarterly Accounts Payable declined from Sep. 2025 (€101 Mil) to Dec. 2025 (€33 Mil) but then increased from Dec. 2025 (€33 Mil) to Mar. 2026 (€96 Mil).

Lakefront Biotherapeutics NV's annual Accounts Payable declined from Dec. 2023 (€135 Mil) to Dec. 2024 (€64 Mil) and declined from Dec. 2024 (€64 Mil) to Dec. 2025 (€33 Mil).

Lakefront Biotherapeutics NV Accounts Payable Related Terms

Lakefront Biotherapeutics NV Accounts Payable Historical Data

* Premium members only.

The historical data trend for Lakefront Biotherapeutics NV's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakefront Biotherapeutics NV Accounts Payable Chart

Lakefront Biotherapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 134.30 133.30 134.65 64.23 32.62

Lakefront Biotherapeutics NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 168.94 133.18 100.63 32.62 95.77
XAMS:LKFT
57GF Score
Lakefront Biotherapeutics NV XAMS:LKFT
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakefront Biotherapeutics NV Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €96 Mil mean?
Lakefront Biotherapeutics NV (XAMS:LKFT) has a Accounts Payable of €96 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Lakefront Biotherapeutics NV and its competitors.
Is Lakefront Biotherapeutics NV's Accounts Payable too high?
Lakefront Biotherapeutics NV's current Accounts Payable is €96 Mil. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's Accounts Payable compare to VRTX and REGN?
Lakefront Biotherapeutics NV's Accounts Payable of €96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Lakefront Biotherapeutics NV and its competitors. Lakefront Biotherapeutics NV's current Accounts Payable is €96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV (XAMS:LKFT) is currently considered Possible Value Trap. The stock's GF Value™ is €109.50, compared to a current price of €24.50 — trading 77.6% below its estimated fair value. The current Accounts Payable is €96 Mil. Lakefront Biotherapeutics NV's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (XAMS:LKFT), the current Accounts Payable is €96 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lakefront Biotherapeutics NV (XAMS:LKFT) Overvalued in 2026?

Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued. The current stock price of €24.50 is trading 77.6% below its estimated GF Value™ of €109.50. GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.

Key valuation signals for XAMS:LKFT:

  • Accounts Payable: €96 Mil
  • GF Value™: €109.50 vs. price of €24.50 (77.6% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the XAMS:LKFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lakefront Biotherapeutics NV Business Description

Address Schalienhoevedreef 20 T, Mechelen, BEL, 2800
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
57GF Score

Get the complete analysis for XAMS:LKFT

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€24.50
Price
€109.50
GF Value